Toggle light / dark theme

Kelsey Moody at Ending Age-Related Diseases 2019

We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.

Dr. Kelsey Moody gave a detailed presentation on macular degeneration, discussing its origins in the lysosomes and how it progresses along with how his company, Ichor Therapeutics, is developing an exogenous enzyme treatment that may cure this crippling disease.

UC San Diego Researchers Isolate Switch that Kills Inactive HIV

Using genetic sequencing, University of California San Diego School of Medicine researchers have identified a principal cellular player controlling HIV reproduction in immune cells which, when turned off or deleted, eliminates dormant HIV reservoirs.

“This is one of the key switches that the HIV field has been searching for three decades to find,” said Tariq Rana, PhD, professor of pediatrics and genetics at UC San Diego School of Medicine. “The most exciting part of this discovery has not been seen before. By genetically modifying a long noncoding RNA, we prevent HIV recurrence in T cells and microglia upon cessation of antiretroviral treatment, suggesting that we have a potential therapeutic target to eradicate HIV and AIDS.”

HIV spreads through certain bodily fluid attacking the immune system and preventing the body from fighting off infections. If left untreated, the virus leads to the disease AIDS.

Nonviral gene therapy to speed up cancer research

With metal organic frameworks.


The nonviral, bioinspired gene delivery method developed by researchers at RMIT University has proven effective in laboratory tests and is safer than standard viral approaches.

Widely considered the next frontier of , gene therapy involves introducing new genes into a patient’s cells to replace missing or malfunctioning ones that cause disease.

As cells are not designed to naturally take up genes or any foreign DNA material, the biggest challenge for gene therapy is getting the therapeutic genes into the cells.

Green tea could hold the key to reducing antibiotic resistance

Scientists at the University of Surrey have discovered that a natural antioxidant commonly found in green tea can help eliminate antibiotic resistant bacteria.

The study, published in the Journal of Medical Microbiology, found that epigallocatechin (EGCG) can restore the activity of aztreonam, an antibiotic commonly used to treat infections caused by the bacterial pathogen Pseudomonas aeruginosa.

P. aeruginosa is associated with serious respiratory tract and bloodstream infections and in recent years has become resistant to many major classes of antibiotics. Currently a combination of antibiotics is used to fight P. aeruginosa. However, these infections are becoming increasingly difficult to treat, as resistance to last line antibiotics is being observed.

SWIFT Provides Synthetic Organ Breakthrough

The ability to create synthetic organs has long been desired in medicine. If we could make synthetic organs for patients from their own cells, we could replace injured or damaged organs without risking the body rejecting the organ. This would have huge implications for the treatment of liver and kidney diseases, among others. For years, scientists have tried to perfect this technology but have been unable to solve the blood flow problem that has made the creation of synthetic organs impossible.

In the last few weeks, a group of scientists appear to have found the solution to this problem or, at least, a major part of it [1].

Reason at Ending Age-Related Diseases 2019

We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.

In his talk, Reason of Repair Biotechnologies addressed the reasons why rejuvenation biotechnology is not proceeding as fast as it could be and discussed the ways in which his company is helping to expedite its development and release.

/* */